We screened for bioactivity in assays representing five different therapeutic areas: diabetes II (PTP1b), cancer (melanoma cells, A2058), anti-oxidants (FRAP), immunomodulation (TNFa) and anti-infection (MRSA, Enterococcus faecalis, Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa). This evidence concerns the gene PTPN1 and infection.